Tuesday, November 17, 2026

Medii x Pfizer launches initiative to accelerate and optimize physician referrals related to heart failure practice support!

Medii and Pfizer have teamed up to launch an initiative in March 2023 to promote close examination of causes in heart failure cases using E-Consult ®︎, an online specialist consultation service exclusively for physicians provided by Medii!

Background of Collaboration

Heart failure is a life-shortening disease that gradually worsens as the heart's function declines, causing shortness of breath and swelling. Since the incidence of heart failure increases with age, a "heart failure pandemic" is predicted in Japan, a super-aging society, where the number of patients is expected to increase dramatically.

There are various causes of heart failure, including hypertension, cardiomyopathy, myocardial infarction, valvular disease, and arrhythmia. Since there is an appropriate treatment for each causative disease, close examination of the cause is extremely important in heart failure cases. Cardiac amyloidosis, a rare, progressive, and fatal disease, is one of the most common causes of heart failure. However, the lack of characteristic symptomatic findings and the lack of experience in diagnosis and treatment of this disease make it difficult for many attending physicians to decide whether to refer patients to specialized facilities or not, and thus diagnosis and appropriate treatment often fail to be made. This often results in failure to diagnose and provide appropriate treatment.

Medii offers "E-Consult ®︎," an online specialist consultation service exclusively for physicians, to bring the knowledge and experience of a limited number of specialist physicians to medical practices in need, particularly in the areas of rare and intractable diseases.

Pfizer is committed to improving the diagnosis rate of heart failure patients, including cardiac amyloidosis, in line with its corporate objective to "create breakthroughs that make a significant difference in patients' lives. Pfizer will collaborate on Medii's efforts to share this specialist knowledge.

This collaboration was born out of Pfizer Healthcare Hub Japan, Pfizer's global initiative to collaborate with startup companies to provide better solutions for patients.

*The press releases of both companies at the start of the study can be found at the following link.
Pfizer Japan Pitch Event at the 3rd Pfizer Healthcare Hub Japan|News|Medii Inc.
https://medii.jp/news/20220930
■ Third Pfizer Healthcare Hub Japan Pitch Event Held to Discuss Solutions with Startups to Deliver Breakthroughs to Patients - | pfizer.co.jp Press Releases
https://www.pfizer.co.jp/pfizer/company/press/2022/2022-09-28

Together, Medii and Pfizer aim to create a society where all patients have access to more specialized care.

Medii has launched a disease awareness website with information on heart failure and cardiac amyloidosis to provide physicians with the latest information on the disease. Furthermore, by utilizing "E-Consult ®︎," which allows physicians involved in heart failure treatment to consult with specialists online free of charge, the site will lead to early diagnosis and appropriate treatment of heart failure and cardiac amyloidosis. The initiative will initially be launched in the Kinki area and will be expanded nationwide. Pfizer will cooperate in this initiative by introducing "E-Consult ®︎" to specialists and general physicians.

Heart Failure/Cardiac Amyloidosis Awareness Site:https://medii.jp/HF_ATTRCMconsultant/

Medii will also hold seminars for physicians to improve the diagnosis rate of heart failure/ cardiac amyloidosis and provide case information.

What is "E-Consult®"?

E-Consult®" provided and operated by Medii is a completely free online service that allows physicians to consult with specialists outside the hospital or in distant locations. Difficult-to-diagnose or non-specialized cases can be consulted anonymously through the chat function on "E-Consult".

More than 800 specialists recommended by physicians in all specialties cooperate in the response process, and the system notifies and matches the most appropriate specialist according to the content of the consulting physician. The system handles all specialties with a focus on immunological intractable diseases and rare diseases where knowledge is not widely available due to the uneven regional distribution of knowledge.
Details:https://medii.jp/e-consult

About Pfizer

Pfizer leverages science and global resources to deliver treatments that help people live longer, healthier lives and significantly improve their lives. We strive to establish standards of quality, safety and value in the discovery, development and manufacture of healthcare products, including innovative medicines and vaccines.
Every day, Pfizer employees contribute to the health of people around the world by providing better prevention and treatment for life- and life-threatening diseases. As one of the world's leading innovative pharmaceutical companies, we are committed to working with healthcare professionals, governments, and communities around the world to ensure that everyone has easy access to reliable healthcare. We have been moving forward for more than 170 years to meet people's expectations.

name of companyPfizer Japan Inc.
EstablishmentAugust 1, 1953
LocationShinjuku Bunka Quint Building, 3-22-7 Yoyogi, Shibuya-ku, Tokyo
representativeAkihisa Harada, President and Representative Director
Business OverviewManufacture, sale, import and export of ethical pharmaceuticals
uniform resouce locatorwww.pfizer.co.jp(Japan Corporation)www.pfizer.com(Global)

About Medii

Medii is developing a business to expand the knowledge of medical specialists online, especially in rare and intractable diseases, which are a major challenge. The company name reflects the company's desire to change the structure of medical care from the inside out (Medii: Latin) from the perspective of both physicians and patients.
With the cooperation and support of many medical specialists, we currently provide three services for physicians: "E-Consultation," "Case Bank," and "E-Confirmation," and are pursuing the essence of medicine with the aim of realizing a world where all people can receive better medical care, no matter what region they live in.

name of companyMedii Corporation
EstablishmentFebruary 20, 2020
LocationTensho Office Shinjuku 3-chome 202, 5-14-12 Shinjuku, Shinjuku-ku, Tokyo
representativeRepresentative Director Doctor Hiroki Yamada
Business OverviewProviding specialist knowledge sharing services
uniform resouce locatorhttps://medii.jp
PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
SourceMedii.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。